Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

New Immuno-Oncology Conference Announced for NYC Combining Business and Clinical Development Strategies
  • USA - English


News provided by

The Conference Forum

May 05, 2015, 08:00 ET

Share this article

Share toX

Share this article

Share toX


New York, New York (PRWEB) May 05, 2015 -- The Conference Forum announced today the launch of Immuno-Oncology 360°, the first program to combine business and clinical development strategies with scientific updates to prepare the market for accelerating immuno-oncology clinical trials. Taking place at Faculty House, Columbia University on June 29-30, Dr Axel Hoos, VP, Oncology R&D, GlaxoSmithKline and conference chair opens the program followed by keynote speaker, Dr Drew Pardoll, Abeloff Professorship of Oncology and Director of Cancer Immunology Johns Hopkins University.

The most well-rounded program to support those leading the immuno-oncology movement

Post this

“With an increasing amount of immuno-oncology (IO) drugs receiving breakthrough FDA approval status and entering fast-tracked clinical trials, we felt an obligation to deliver the most well-rounded program to support those leading the immuno-oncology movement,” said Kate Woda, Conference Director for the Immuno-Oncology 360° program.

The Immuno-Oncology 360° program is developed in partnership with industry, academia, the investment community, government and providers to enable attendees to gain a panoramic perspective. This includes how to optimize clinical strategy, investigate scientific models and approaches to IO and how to capitalize on market opportunities that will ultimately help revolutionize the way cancer is treated.

"Immuno-Oncology has the potential to become the mainstream therapy for all cancer,” said Dr. Howard Kaufman, Chief Surgical Officer and Associate Director of Rutger’s Cancer Institute of NJ in an interview with The Conference Forum. "We are getting very long term durable responses from cases we think can maybe even cure with this therapy."

The speaking faculty at Immuno-Oncology 360° includes:

Roy Baynes, MD, PhD, SVP, Global Clinical Development, Merck Research Labs
Arie Belldegrun, MD, FACS, Chairman, President and CEO, Kite Pharma
Tai-Tsang Chen, PhD, Executive Director / Adjunct Assistant Professor of Biostatistics, Bristol-Myers Squibb / Columbia University
Jason Coloma, Global Head Venture & Innovation, Roche Pharmaceuticals
Laurence J.N. Cooper, MD, PhD, Director, Immunology Laboratory of Physician Scientists, Department of Immunology, University of Texas, MD Anderson Cancer Center
Greg Dombal, Chief Operating Officer, Halloran Consulting Group
David Donabedian, PhD, VP and Head, Ventures and Early Stage Collaborations, AbbVie
James Gulley, MD, PhD, Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research National Cancer Institute
Omid Hamid, MD, Chief, Translational Research and Immunotherapy / Director, Melanoma Therapeutics, The Angeles Clinic and Research Institute
Axel Hoos, MD, PhD, Vice President, Oncology R&D, GlaxoSmithKline
Ramy Ibrahim, MD, Clinical Vice President, Immuno-Oncology, AstraZeneca
Michael Kalos, PhD, Chief Scientific Officer, Cancer Immunobiology, Eli Lilly and Co.
Howard Kaufman, MD, FACS, Chief Surgical Officer, Assoc. Director / President, Rutgers Cancer Institute of New Jersey / Society for Immunotherapy of Cancer (SITC)
Michael King Jr., Managing Director & Senior Biotech Analyst, JMP Securities
Ira Klein, MD, MBA, FACP, National Medical Director, Clinical Thought Leader, Office of the CMO, Aetna
Philippe Lopes-Fernandes, SVP & Head of Global Licensing & Business Development, EMD Serono
Jennifer Mataraza, Principal Investigator, Oncology Biotherapeutics, Novartis
Ian McCaffery, PhD, Head, Companion Diagnostics, Oncology Biomarker Development, Genentech Inc.
Drew Pardoll, MD, PhD, Abeloff Professorship of Oncology and Director of Cancer Immunology, Johns Hopkins University
Anna Pavlick, DO, Associate Professor, Hematology and Medical Oncology, Medical Director, Clinical Trials Office, Perlmutter Cancer Center, NYU Langone Medical Center
Edith A. Perez, MD, Deputy Director at Large / Group Vice Chair, Mayo Clinic Cancer Center / Alliance for Clinical Trials in Oncology
Andrea Perrone, MD, Head of Clinical Imaging, Translational Medicine, Merck
Leonard Saltz, MD, Chief, Gastrointestinal Oncology Service and Head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center
Michael Schmidt, PhD, Director, Biotechnology, Leerink Partners
Mark Simon, Partner, Torreya Partners
Elena Spanjaard, PhD, Director, Worldwide Research & Development, Regulatory, Pfizer
Robert Stein, MD, PhD, Chief Scientific Officer, Agenus, Inc.
Mary Stober Murray, MBA, Associate Director, Advocacy, Bristol-Myers Squibb
William Tunno, Head of Global Oncology, Patient Advocacy and Professional Relations, Boehringer Ingelheim
Kristin Viswanathan, Director, Health Policy and Research, BIO
Robert Wasserman, MD, VP, Oncology Global TA Head, Medical Leadership, Covance
Tal Zaks, MD, PhD, Chief Medical Officer, Moderna Therapeutic

For more information about the Immuno-Oncology 360° program, visit http://theconferenceforum.org/conferences/immuno-oncology-360/overview/

About The Conference Forum:
The Conference Forum develops specialized events for professionals in the life science and healthcare industries. We currently offer conferences for R&D leaders, clinical development professionals, biotech executives, VCs, drug delivery specialists and pharma/generic government directors. Our mission is to create the best content, exchange ideas and solutions among peers and provide quality networking for Pharmaceutical and Biotech professionals. http://www.theconferenceforum.org

About Society for Immunotherapy of Cancer (SITC):
SITC is a 501 (c)(3) non-profit medical professional society of influential scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. http://www.sitcancer.org

Jessica Rothenberg, The Conference Forum, http://www.theconferenceforum.org, 646-490-2712, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.